在前列腺癌容积旋转调强放疗-立体定向体部放疗中注射水凝胶间隔物增加了分次内前列腺在向前和向上方向的最大位移
该回顾性研究纳入2018—2019年在本机构接受容积旋转调强放疗-立体定向体部放疗并监测前列腺运动的38例前列腺癌患者,比较水凝胶间隔物组(8例,33个分次)与非间隔物组(30例,148个分次)的分次内前列腺最大位移;结果显示间隔物组在向前和向上方向的最大位移更大(向前0.45±0.06 mm vs 1.16±0.35 mm,P=0.0023;向上0.47±0.07 mm vs 0.97±0.24 mm,P=0.014),作者认为该差异似乎不干扰水凝胶间隔物的剂量学优势,故不推荐常规避免使用水凝胶间隔物。
要点
- 水凝胶间隔物组向前最大位移0.45±0.06 mm vs 非间隔物组1.16±0.35 mm(P=0.0023)。
- 水凝胶间隔物组向上最大位移0.47±0.07 mm vs 非间隔物组0.97±0.24 mm(P=0.014)。
- 作者认为该差异似乎不干扰水凝胶间隔物的剂量学优势,不推荐常规避免使用水凝胶间隔物。
核心结论
- 作者认为在容积旋转调强放疗-立体定向体部放疗期间,注射水凝胶间隔物的患者分次内前列腺在向上和向前方向的最大位移更大。
- 作者认为该差异似乎不干扰水凝胶间隔物的剂量学优势,故不推荐常规避免使用水凝胶间隔物。
研究设计与样本
- 回顾性评估2018—2019年在本机构接受根治性容积旋转调强放疗-立体定向体部放疗并监测前列腺运动的前列腺癌患者38例。
- 符合使用指征时向患者提议注射水凝胶间隔物(SpaceOAR系统,Boston Scientific,美国马尔伯勒)作为选项。
- 使用4维经会阴超声设备Clarity 4D超声系统(Elekta AB)监测分次内前列腺运动,监测上下、左右和前后方向并计算矢量长度。
- 检测每个分次各方向的最大分次内位移(MID),计算每例患者MID的均值,采用非配对t检验比较非间隔物组与间隔物组的MID。
主要发现
- 间隔物组8例共33个分次,非间隔物组30例共148个分次。
- 向上MID:非间隔物组0.47±0.07 mm vs 间隔物组0.97±0.24 mm(P=0.014),间隔物组较非间隔物组升高。
- 向下MID:非间隔物组1.07±0.11 mm vs 间隔物组1.03±0.25 mm(P=0.88)。
- 向左MID:非间隔物组0.74±0.08 mm vs 间隔物组0.87±0.27 mm(P=0.55)。
- 向右MID:非间隔物组0.67±0.08 mm vs 间隔物组0.92±0.21 mm(P=0.17)。
临床怎么用
- 作者认为该差异似乎不干扰水凝胶间隔物的剂量学优势,不推荐常规避免使用水凝胶间隔物。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The aim of this study was to clarify the association between intrafractional prostate shift and hydrogel spacer. METHODS: Thirty-eight patients who received definitive volumetric modulated arc therapy (VMAT)-stereotactic body radiation therapy (SBRT) for prostate cancer with prostate motion monitoring in our institution in 2018-2019 were retrospectively evaluated. In order to move the rectum away from the prostate, hydrogel spacer (SpaceOAR system, Boston Scientific, Marlborough, the United States) injection was proposed to the patients as an option in case of meeting the indication of use. We monitored intrafractional prostate motion by using a 4-dimensional (4D) transperineal ultrasound device: the Clarity 4D ultrasound system (Elekta AB). The deviation of the prostate was monitored in each direction: superior-inferior, left-right, and anterior-posterior. We also calculated the vector length. The maximum intrafractional displacement (MID) per fraction for each direction was detected and mean of MIDs was calculated per patient. The MIDs in the non-spacer group and the spacer group were compared using the unpaired t-test. RESULTS: We reviewed 33 fractions in eight patients as the spacer group and 148 fractions in 30 patients as the non-spacer group. The superior MID was 0.47 ± 0.07 (mean ± SE) mm versus 0.97 ± 0.24 mm (P = 0.014), the inferior MID was 1.07 ± 0.11 mm versus 1.03 ± 0.25 mm (P = 0.88), the left MID was 0.74 ± 0.08 mm versus 0.87 ± 0.27 mm (P = 0.55), the right MID was 0.67 ± 0.08 mm versus 0.92 ± 0.21 mm (P = 0.17), the anterior MID was 0.45 ± 0.06 mm versus 1.16 ± 0.35 mm (P = 0.0023), and the posterior MID was 1.57 ± 0.17 mm versus 1.37 ± 0.22 mm (P = 0.56) in the non-spacer group and the spacer group, respectively. The max of VL was 2.24 ± 0.19 mm versus 2.89 ± 0.62 mm (P = 0.19), respectively. CONCLUSIONS: Our findings suggest that maximum intrafractional prostate motion during VMAT-SBRT was larger in patients with hydrogel spacer injection in the superior and anterior directions. Since this difference seemed not to disturb the dosimetric advantage of the hydrogel spacer, we do not recommend routine avoidance of the hydrogel spacer use.
引用
- Sawayanagi S, Yamashita H, Ogita M, et al. Injection of hydrogel spacer increased maximal intrafractional prostate motion in anterior and superior directions during volumetric modulated arc therapy-stereotactic body radiation therapy for prostate cancer. Radiat Oncol. 2022. PMID: 35197092. doi:10.1186/s13014-022-02008-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。